The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2022 | HPN328, a tri-specific T-cell engager, in SCLC and neuroendocrine cancers
Melissa Johnson, MD, Sarah Cannon Research Institute, Nashville, TN, describes the interim results of an ongoing phase I/IIa study (NCT04471727) of HPN328, a tri-specific, DLL3-targeting T-cell engager, in patients with small cell lung cancer (SCLC) and other neuroendocrine cancers. The investigational therapy binds to T-cells and stimulates their activity. Three doses were assessed and partial responses were reported in a number of patients. HPN328 additionally was well tolerated, with cases of cytokine release syndrome being manageable. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL
Transcript
Tomorrow I’ll present a poster on this tri-specific T-cell engager made by Harpoon. It’s a DLL3 specific, tri-specific that also binds to T-cells, stimulates the T-cells and introduces them into the tumor.
So we’ve treated about three different dose levels. We have had a couple partial responses and some other patients with target lesion shrinkage, and so the dose escalation continues...
Tomorrow I’ll present a poster on this tri-specific T-cell engager made by Harpoon. It’s a DLL3 specific, tri-specific that also binds to T-cells, stimulates the T-cells and introduces them into the tumor.
So we’ve treated about three different dose levels. We have had a couple partial responses and some other patients with target lesion shrinkage, and so the dose escalation continues. It’s been well tolerated with manageable cytokine release.
Read more...
